Please assess the completion status of the following clinical trial:

Trial Title: Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. More than 18 years of age~2. Patients suffering from one of the following chronic inflammatory intestinal disease:~   * Steroid-dependent Chron's Disease or Ulcerative Colitis following ECCO definition or mild-moderate active UC ( Powell Tuck between 3 and 14- an index of 14 was allowed; endoscopic Baron score \>1) refractory to mesalazine.~3. Disease extension over the rectum (at least 15 cm) in patients suffering from Ulcerative Colitis~4. Patients willing and be able to give written informed consent.~Exclusion Criteria:~1. Intestinal sub occlusion or a suspected abdomen abscess or a severe degree of the disease (CDAI \> 450) in patient suffering from Chron's Disease~2. Patient affected by a severe Ulcerative Colitis (more than 6 evacuations of liquid, mucous-blooding stools combined at least one systemic sign as body temperature \> 37.8 °C, heart rate \< 90 bpm, ESR \> 30 mm/h or haemoglobin \< 10.5 g/dL)~3. Severe concurrent disease(s) as:~   * Medullar deficit: white blood cells \< 3000/mm3; platelets \< 75000/mm3; haemoglobin \< 10 g/dL;~  * Hepatic diseases presenting total bilirubin ≥ 3 mg/dL; AST (GOT) ≥ 5 UNL; alkaline phosphatase ≥ 5 UNL:~  * Renal failure with serum creatinine ≥ 3 mg/dL;~  * Heart failure~  * Respiratory failure~  * Disabling neurological diseases~  * Neoplasia~  * Patient deemed candidate to surgery due to Chron's Disease or Ulcerative Colitis~  * Chronic alcohol or drug abuse~  * Patient for whom the use of steroids is contraindicated (e.g. systemic infections)~4. Treatment with Infliximab in the previous 4 months~5. Pregnant woman or female for whom the possibility of a pregnancy during the study could not be excluded.~6. Non-collaborating patient or subject unable to regularly undergo the scheduled study procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dex 21-P (Type: EXPERIMENTAL): In this arm a dose of 20 ml of Dex 2-P solution was administered every 15 or 30 days for a total of 3 or 6 treatment procedures, respectively.~Specifically, steroid-dependant IBD patients had to undergo a total of 6 procedures at one month interval, while active mesalazine refractory UC patients had to undergo a total of 3 procedures at 15 days interval.~Every procedure implies the collection and re-infusion of autologous erythrocytes previously loaded with Dex 21-P.
- Placebo (Type: PLACEBO_COMPARATOR): In this arm placebo solution was administered every 15 or 30 days for a total of 3 or 6 treatment procedures, respectively.~Specifically, steroid-dependant IBD patients had to undergo a total of 6 procedures at one month interval, while active mesalazine refractory UC patients had to undergo a total of 3 procedures at 15 days interval.~Every procedure implies the collection and re-infusion of autologous erythrocytes previously NOT loaded with Dex21-P.

Based on this trial design, predict the completion outcome and termination type (if applicable).